173 related articles for article (PubMed ID: 1864551)
1. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation.
Haanen C; De Witte T; Plas A; Schattemberg T
Haematologica; 1991 Mar; 76 Suppl 1():22-8. PubMed ID: 1864551
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
3. Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells.
Preijers FW; van Hennik PB; Schattenberg A; Ruijs P; Ploemacher RE; de Witte T
Bone Marrow Transplant; 1999 May; 23(10):1061-70. PubMed ID: 10373074
[TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
5. Using elutriation to engineer bone marrow allografts.
Noga SJ; Wagner JE; Rowley SD; Davis JM; Vogelsang GB; Hess AD; Saral R; Santos GW; Donnenberg AD
Prog Clin Biol Res; 1990; 333():345-59; discussion 360-1. PubMed ID: 2137932
[TBL] [Abstract][Full Text] [Related]
6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
[TBL] [Abstract][Full Text] [Related]
8. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
9. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
[TBL] [Abstract][Full Text] [Related]
10. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
[TBL] [Abstract][Full Text] [Related]
11. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo depletion of T cells.
Arnold R; Bunjes D; Wiesneth M; Hertenstein B; Theobald M; Heimpel H; Hale G; Waldmann H
Bone Marrow Transplant; 1993; 12 Suppl 3():S11-2. PubMed ID: 8124250
[TBL] [Abstract][Full Text] [Related]
13. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
de Witte T; Preijers F; Schattenberg A
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
[No Abstract] [Full Text] [Related]
15. Separation of rat bone marrow cells by counterflow centrifugal elutriation: a model for studying the effects of lymphocyte depletion.
Wagner JE; Donnenberg AD; Noga SJ; Wiley JM; Yeager AM; Vogelsang GB; Hess AD; Santos GW
Exp Hematol; 1988 Mar; 16(3):206-12. PubMed ID: 3257446
[TBL] [Abstract][Full Text] [Related]
16. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD
J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073
[TBL] [Abstract][Full Text] [Related]
17. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
18. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
19. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
20. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]